Publication date: Sep 06, 2025
“The study indicates that starting metformin early after a COVID-19 diagnosis could substantially reduce the risk of long COVID in adults with excess body weight. Importantly, the results mirror those from controlled clinical trials, suggesting that the benefit extends beyond trial settings into routine clinical practice. However, the study had limitations. Since only overweight or obese adults were included, the findings may not apply to individuals with normal BMI. The population included adults with a body mass index (BMI) of 25 kg/m or higher who had a documented COVID-19 infection. Additionally, as this was an observational analysis, the authors caution that causality cannot be fully established. Clinical Infectious Diseases. https://doi. org/10. 1093/cid/ciaf429
| Concepts | Keywords |
|---|---|
| Colleagues | Adults |
| July | Clinical |
| Minnesota | Covid |
| Overweight | Days |
| Postcovid | Early |
| Findings | |
| Long | |
| Metformin | |
| Obese | |
| Overweight | |
| Pcc | |
| Risk | |
| Study | |
| Symptom | |
| Trial |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | role |
| drug | DRUGBANK | Tropicamide |
| disease | MESH | causality |
| drug | DRUGBANK | Methionine |
| drug | DRUGBANK | Factor IX Complex (Human) |
| disease | MESH | contraindications |
| disease | MESH | COVID-19 |
| disease | MESH | infection |
| disease | MESH | Infectious Diseases |
| disease | IDO | symptom |
| drug | DRUGBANK | Dihydrotachysterol |
| disease | MESH | overweight |
| disease | MESH | Long COVID |
| drug | DRUGBANK | Metformin |